KRN5500 Demonstrated Significant Decrease in the Intensity of Neuropathic Pain in Patients with Cancer
DARA BioSciencesA spicamycin derivative (KRN5500) provides neuropathic pain relief in patients with advanced cancer: a placebo-controlled, proof-of-concept trial.